Anne Roberts, UCSD Thornton Hospital, La Jolla, San Diego, USA, spoke to delegates at the International Symposium on Endovascular Therapy (ISET), 18–23 January 2013, Miami, Florida, USA, on the topic of indications for retrieval inferior vena cava filters, retrievable rates and contemporary issues which accompany filter implementation.
On the 27 February 2013, Toshiba announced that it would be showcased at the European Society of Radiology’s (ECR) Annual Meeting (7–11 March 2013, Vienna, Austria). The Aquilion ONE/ ViSION Edition is said by the company to have faster rotation speed of just 0.275 seconds which is applicable for all routine applications. A wider 78 cm gantry bore improves patient comfort and access. In combination with AIDR 3D, the ViSION Edition provides fast and robust low dose imaging for all patient examinations with negligible impact of reconstruction time, according Toshiba.
Los pacientes de diabetes que toman la clase más nueva de medicamentos para controlar los niveles de azúcar en la sangre tienen el doble de probabilidades de sufrir de pancreatitis que los que toman otros medicamentos para controlar el azúcar
Surefire Medical, Inc., the developer of a new class of infusion systems designed to maximize targeted delivery of embolization agents without reflux, today announced CE Mark approval for its Surefire Infusion System ST/LT and Surefire Specialty Catheters. The company will launch its latest line of microcatheters and specialty catheters for the interventional radiology and interventional oncology markets in Europe during the second quarter 2013, and immediately in New Zealand, where regulatory approval has also been granted
BSD Medical Corporation (BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems utilizing heat therapy to treat cancer, announced today a 319% increase in sales of its MicroThermX® Microwave Ablation System (MicroThermX®) disposable SynchroWave antennas during the first five months of fiscal 2013, when compared to the first five months of fiscal 2012 sales of its SynchroWave antennas. BSD President Harold Wolcott stated, “This increase in sales of disposable antennas is indicative of the growing acceptance and use of MicroThermX® products in the ablation market
PneumRx, Inc., a leader in interventional pulmonology, announced the first U.S. patients treated with PneumRxs Lung Volume Reduction Coils (LVRCs) for severe emphysema. Dr. Charlie Strange, of the Medical University of South Carolina, and Dr. Frank Sciurba, of the University of Pittsburgh and UPMC, treated the first US patients in the FDA-approved RENEW Study. The RePneu® LVRC, a minimally invasive medical implant designed to treat the symptoms of severe emphysema, is intended to improve lung function, exercise ability and quality of life for this underserved patient population
The Spectranetics Corporation (SPNC) today announced final results from the PATENT (Photo-Ablation using the TURBO-Booster(R) and Excimer Laser for In-Stent Restenosis Treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis (ISR) in the femoropopliteal artery in the leg. ISR occurs as a result of narrowing of the artery in patients who have undergone stenting for the treatment of peripheral arterial disease (PAD). There is currently no FDA-cleared or approved device to treat peripheral in-stent restenosis, which remains a major unsolved medical problem
Pregnant women who develop iliofemoral deep vein thrombosis often forgo the most effective treatment for fear of harming the baby. Yet treatment to remove the clot is not only safe, it can prevent serious problems, and death, suggests research presented at the International Symposium on Endovascular Therapy (ISET), 19–23 January 2013, Miami, Flordia, USA.
Munich Study Concludes 15 Year Outcome Data May Warrant Closing of Investigational Phase for HIFU
Un dispositivo magnético implantado podría ofrecer una nueva opción de tratamiento a las personas con acidez crónica que no se controla con medicamentos, sugiere un pequeño estudio.
20-Year-Old Tiernee Gonzalez Begins Producing Urine Day Before Scheduled Surgery to Implant Permanent Catheter. At only 20 years old, Tiernee Gonzalez has been battling two major diseases for most of her young life: heart failure and kidney failure. When she became the first patient at Cincinnati Children s Hospital Medical Center to receive the SynCardia temporary Total Artificial Heart on Nov. 9, her doctors hoped it would bring her one step closer to winning her battle against end-stage heart failure. What they didn t expect, was that it would also help save her one remaining kidney
Furthering its commitment to advancing the treatment of patients diagnosed with ESRD (End Stage Renal Disease), Argon Medical Devices, Inc. takes another leap forward with the launch of the Cleaner15 Rotational Thrombectomy System. The addition of Cleaner15 to Argon Medical s product portfolio provides physicians with another weapon in their arsenal to safely and effectively restore patency in occluded arteriovenous fistulae and synthetic grafts.
Societies form new foundation, collaborate on multicenter trial to improve patient care
Patients who received minimally invasive treatment with yttrium-90 (Y-90) radioactive beads to treat colorectal cancer that had spread to the liver lived almost a year longer compared to those who received the standard of care therapy, data presented at the 5th annual Symposium on Clinical Interventional Oncology, in collaboration with the International Symposium on Endovascular Therapy (ISET) has suggested.
Varian Medical Systems has received FDA 510(k) clearance for the company s Edge radiosurgery suite, a new dedicated system for performing advanced radiosurgery using real-time tumour tracking and motion management technologies.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos